Literature DB >> 15838188

Prevention with gay and bisexual men living with HIV: rationale and methods of the Seropositive Urban Men's Intervention Trial (SUMIT).

Richard J Wolitski1, Jeffrey T Parsons, Cynthia A Gómez, David W Purcell, Colleen C Hoff, Perry N Halkitis.   

Abstract

OBJECTIVES: To provide a public health rationale for prevention with HIV-seropositive gay and bisexual men and to describe the methods of the Seropositive Urban Men's Intervention Trial (SUMIT).
DESIGN: A randomized intervention trial.
METHODS: Self-identified HIV-positive gay and bisexual men were recruited from community-based venues in New York City and San Francisco. Eligible participants completed an A-CASI baseline assessment, were asked to provide samples for sexually transmitted infection (STI) testing, and were randomly assigned to either a single-session intervention or a six-session enhanced intervention designed to reduce HIV transmission risk and promote serostatus disclosure. Participants who attended the first intervention session were assessed 3 and 6 months post-intervention. STI testing was offered at the 6-month assessment.
RESULTS: A total of 1168 self-identified HIV-seropositive gay and bisexual men completed the baseline assessment, and 1110 of these (95%) opted for STI testing. A total of 811 attended the first intervention session, of which 85% were assessed at 3 months and 90% were assessed at 6 months. Of those assessed at 6 months, 92% (670/729) provided a blood or urine sample for STI testing.
CONCLUSION: SUMIT demonstrates the feasibility and acceptability of prevention research with HIV-seropositive gay and bisexual men. The study provides new information about the sexual behavior, serostatus disclosure practices, and the efficacy of an intervention to reduce HIV transmission risk.

Entities:  

Mesh:

Year:  2005        PMID: 15838188     DOI: 10.1097/01.aids.0000167347.77632.cd

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  7 in total

1.  Assessing mediation in HIV intervention studies.

Authors:  Felicia P Hardnett; Sherri L Pals; Craig B Borkowf; Jeffrey Parsons; Cynthia Gomez; Ann O'Leary
Journal:  Public Health Rep       Date:  2009 Mar-Apr       Impact factor: 2.792

2.  ACASI Gender-of-Interviewer Voice Effects on Reports to Questions about Sensitive 
Behaviors Among Young Adults.

Authors:  Jennifer Dykema; Kerryann Diloreto; Jessica L Price; Eric White; Nora Cate Schaeffer
Journal:  Public Opin Q       Date:  2012-07

3.  Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010.

Authors:  Lori A J Scott-Sheldon; Tania B Huedo-Medina; Michelle R Warren; Blair T Johnson; Michael P Carey
Journal:  J Acquir Immune Defic Syndr       Date:  2011-12-15       Impact factor: 3.731

Review 4.  Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004.

Authors:  Cynthia M Lyles; Linda S Kay; Nicole Crepaz; Jeffrey H Herbst; Warren F Passin; Angela S Kim; Sima M Rama; Sekhar Thadiparthi; Julia B DeLuca; Mary M Mullins
Journal:  Am J Public Health       Date:  2006-11-30       Impact factor: 9.308

5.  Church-Based HIV Screening in Racial/Ethnic Minority Communities of California, 2011-2012.

Authors:  Malcolm V Williams; Kathryn Pitkin Derose; Frances Aunon; David E Kanouse; Laura M Bogart; Beth Ann Griffin; Ann C Haas; Deborah Owens Collins
Journal:  Public Health Rep       Date:  2016-08-22       Impact factor: 2.792

6.  Non-Paraphilic Compulsive Sexual Behavior and Psychiatric Co-morbidities in Gay and Bisexual Men.

Authors:  Jon Morgenstern; Frederick Muench; Ann O'Leary; Milton Wainberg; Jeffrey T Parsons; Eric Hollander; Leah Blain; Thomas Irwin
Journal:  Sex Addict Compulsivity       Date:  2011-08-31

7.  Hidden Empirical Research Ethics: A Review of Three Health Journals from 2005 through 2006.

Authors:  James M Dubois; Rebecca L Volpe; Erica K Rangel
Journal:  J Empir Res Hum Res Ethics       Date:  2008-09       Impact factor: 1.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.